Next-Generation Obesity Therapeutics: Long-Acting Antibodies for Improved Quality of Weight Loss

Time: 1:30 pm
day: Day Two

Details:

• Evaluating how the long-acting nature of next-generation antibodies improves patient adherence and convenience, providing a clear advantage in sustaining long-term weight loss and ensuring superior patient outcomes
• Discussing how these antibodies are being engineered for improved tolerability and reduced side effects, offering a clear benefit in enhancing patient comfort and ensuring more durable treatment engagement
• Analyzing how these long-acting therapies are being designed to not only reduce body weight but also improve body composition, providing a distinct advantage in promoting a higher quality of weight loss with a focus on muscle preservation and metabolic health

Speakers:

Cory Schwartz Cory Schwartz, PhD, is Director of Drug Discovery at iBio, Inc., where he leads early-stage programs from target identification to candidate selection, leveraging AI-driven antibody Read more